Profusa, Inc. news
Profusa, a digital health company that is pioneering the next generation of personalized medicine, today announced research findings that suggest the company’s Lumee® Oxygen Platform may help improve the clinical management of patients with critical limb ischemia (CLI) who are undergoing endovascular revascularization treatment (EVT). The data, from a recent post-market clinical study called OMNIA (Oxygen Monitoring Near Ischemic Ar
Profusa, a digital health company that is pioneering the next generation of personalized medicine, today announced it has received Conformité Européenne (CE) Mark approval to market its Wireless Lumee® Oxygen Platform for continuous, real-time monitoring of tissue oxygen in patients with potential acute and/or chronic changes in tissue oxygen levels who may b
Profusa Software and Systems Lead, Kevin Zhao, has been selected to participate in the Defense Advanced Research Projects Agency’s (DARPA) 60th Anniversary Symposium (D60) as a DARPA Riser. The D60 Symposium takes place from September 5-7 at the Gaylord National Resort and Convention Center, National Harbor, Maryland.
DARPA hand-selected 50 early-career scientists and engineers identified as possible futu
Up until now, local inflammation and scar tissue from the so-called “foreign body response” has prevented the development of in-body sensors capable of continuous, long-term monitoring of body chemistry. But today scientists are presenting results showing tiny biosensors that become one with the body have overcome this barrier, and stream data to a mobile phone and to the cloud for personal and medical use.
“While fitness trackers and other wearab
Profusa, Inc., a developer of tissue-integrated biosensors for continuous monitoring of body chemistry, today announced that it received the CE Mark to market its Lumee Oxygen Platform™ for continuous, real-time monitoring of tissue oxygen. The company will initially market the system for monitoring tissue oxygen in the treatment of peripheral artery disease (PAD). With